Skip to main
CAI

CAI (CAI) Stock Forecast & Price Target

CAI (CAI) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 36%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Caris Life Sciences is a patient-centric, next-generation AI TechBio company that offers several precision molecular diagnostic solutions spanning early detection, minimal residual disease ("MRD") tracking, therapy selection, and treatment monitoring, all on the same technology platform. With strong partnerships and reimbursement coverage, and a leading market position in tissue-based profiling, Caris is well positioned to continue its impressive revenue growth. With a focus on innovation and a strong pipeline, Caris has the potential for further growth and success in the precision medicine industry.

Bears say

Caris Life Sciences is a patient-centric, next-generation AI TechBio company with a strong focus on comprehensive molecular information and artificial intelligence/machine learning algorithms. However, despite the potential of its technology, Caris is facing challenges with a slower-than-expected adoption of its therapy selection volumes and missed revenue targets in the first quarter of 2026. In addition, the company faces risks in terms of litigation and legal challenges due to the competitive marketplace it operates in. These concerns, coupled with the uncertainty regarding government and commercial payer coverage for its solutions, and its reliance on limited third-party suppliers, contribute to a negative outlook on Caris Life Sciences' stock.

CAI (CAI) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 36% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CAI and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CAI (CAI) Forecast

Analysts have given CAI (CAI) a Buy based on their latest research and market trends.

According to 11 analysts, CAI (CAI) has a Buy consensus rating as of May 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CAI (CAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.